- JP-listed companies
- Ownership
(504A) Shareholders
Market cap
¥38.7B
P/E ratio
Innovacell develops cell therapy treatments for incontinence using patients' own muscle cells to restore damaged muscle function. The company has three products in clinical trials with potential first-mover advantage in this specialized field.
大株主
| （単位：千株） | 2025/12 |
|---|---|
| Peppermint Grove Limited | 3,609.815 10.83% |
| INSANNA Stiftung | 3,607.988 10.82% |
| シーズ・インベストメント有限責任事業組合 | 2,464.1 7.39% |
| シーガー・ジェイソン | 2,291.721 6.87% |
| ノビック・コーリン | 2,291.721 6.87% |
| マークシュタイナー・ライナー | 2,140.628 6.42% |
| 坂野 敦 | 1,643.914 4.93% |
| Glymur Biotech Ventures LP | 1,339.508 4.02% |
| アルフレッサ | 1,176.471 3.53% |
| 山田 敏治 | 791.7 2.37% |
| 計 | 21,357.566 64.07% |